Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY. 2024 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsPresent...
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the q...
A director at Hawthorn Bancshares Inc bought 15,000 shares at 19.626USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024. Details of the panel discussion are as follow: BTIG Obesity Health ForumPanel Title: CB1 Axis Therapies for ObesityDate: Wednesday, May 8, 2024Presentation Time: 3:00 p.m. ET For further inf...
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the annual meeting, to be held May 31-June 4, 2024 in Chicago, IL. CRB-701 (SYS6002) is a next-generation antibody-drug-conju...
Hawthorn Bancshares Announces Cash Dividend JEFFERSON CITY, Mo., April 24, 2024 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK) announced today that its Board of Directors approved a quarterly cash dividend of $0.19 per common share, payable July 1, 2024 to shareholders of record at the close of business on June 15, 2024, which represents an increase of $0.02 per common share from the prior quarter's dividend. About Hawthorn Bancshares, Inc. Hawthorn Bancshares, Inc., a financial-bank holding company headquartered in Jefferson City, Missouri, is the parent company of Hawtho...
Hawthorn Bancshares Reports First Quarter 2024 Results JEFFERSON CITY, Mo., April 24, 2024 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK), (the “Company”), the bank holding company for Hawthorn Bank, reported first quarter 2024 net income of $4.5 million and earnings per diluted share (“EPS”) of $0.63. First Quarter 2024 Results Net income of $4.5 million, or $0.63 per diluted share, an increase of 34.0% per diluted share from the first quarter 2023 (the "prior year quarter")Net interest margin, fully taxable equivalent ("FTE") of 3.39%Return on average assets and equity o...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.